Literature DB >> 3801767

In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists.

S Conolan, M J Quinn, D A Taylor.   

Abstract

The abilities of ketanserin, ritanserin, R56413 and LY53857 to inhibit 5-hydroxytryptamine (5-HT) and noradrenaline-induced vasoconstrictor responses both in vitro and in vivo and to lower blood pressure in the rat, were compared. In the isolated perfused mesenteric artery preparation of the rat all of the compounds tested were found to be potent inhibitors of 5-HT-induced vasoconstrictor responses. Ritanserin was the most potent compound, producing more than 50% inhibition of a near maximal response to 5-HT at a concentration of 10(-11) M. All four compounds were found to be competitive antagonists of noradrenaline; ketanserin being the most potent with a pA2 value of 7.64 +/- 0.06. 5-HT-induced pressor responses in the pithed rat were inhibited by low doses (0.3-10 micrograms kg-1) of the four compounds. Ketanserin, at doses of 0.1-3.0 mg kg-1, resulted in rightward shifts of the control dose-response curve to noradrenaline in the pithed rat. None of the other compounds had any significant effect on the noradrenaline-induced pressor responses. Ketanserin (0.1-1 mg kg-1) produced a dose-dependent decrease in the mean arterial blood pressure of anaesthetized rats. The maximum decrease in blood pressure observed following a dose of 1 mg kg-1 ketanserin was 73.7 +/- 4.7 mmHg. The other compounds at doses of 1.0-3.0 mg kg-1 produced a decrease in blood pressure of a lesser magnitude than that following ketanserin. In addition, this effect did not appear to be dose-dependent. It is suggested that the acute hypotensive effect of ketanserin results predominantly from alpha 1-adrenoceptor blockade. The involvement ofantagonism of 5-HT2 receptors in the hypotensive effect of the other compounds tested cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801767      PMCID: PMC1917053          DOI: 10.1111/j.1476-5381.1986.tb11128.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  THE EFFECT OF SYMPATHETIC NERVE STIMULATION OF VASOCONSTRICTOR RESPONSES IN PERFUSED MESENTERIC BLOOD VESSELS OF THE RAT.

Authors:  D D MCGREGOR
Journal:  J Physiol       Date:  1965-03       Impact factor: 5.182

2.  The influence of prostaglandins on noradrenaline-induced vasoconstriction isolated perfused mesenteric blood vessels of the rat.

Authors:  I M Coupar; P L McLennan
Journal:  Br J Pharmacol       Date:  1978-01       Impact factor: 8.739

3.  A comparison of pre- and post-junctional potencies of several alpha-adrenoceptor agonists in the cardiovascular system and anococcygeus muscle of the rat. Evidence for two types of post-junctional alpha-adrenoceptor.

Authors:  J R Docherty; J C McGrath
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-06       Impact factor: 3.000

4.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

5.  Characterization of the antihypertensive properties of ketanserin (R 41 468) in rats.

Authors:  H O Kalkman; P B Timmermans; P A Van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

6.  Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.

Authors:  G J Wenting; A J Man in 't Veld; A J Woittiez; F Boomsma; M A Schalekamp
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-20

7.  Vascular activity of ketanserin (R 41 468), a selective 5-HT2 receptor antagonist.

Authors:  J M Van Nueten; R Xhonneux; P M Vanhoutte; P A Janssen
Journal:  Arch Int Pharmacodyn Ther       Date:  1981-04

8.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

9.  Postsynaptic alpha 1- and alpha 2-adrenoceptors in the circulatory system of the pithed rat: selective stimulation of the alpha 2-type by B-HT 933.

Authors:  P B Timmermans; P A Van Zwieten
Journal:  Eur J Pharmacol       Date:  1980-05-02       Impact factor: 4.432

10.  The antihypertensive effects of a pure and selective serotonin-receptor blocking agent (R 41 468) in elderly patients.

Authors:  J De Cree; J Leempoels; W De Cock; H Geukens; H Verhaegen
Journal:  Angiology       Date:  1981-02       Impact factor: 3.619

View more
  6 in total

1.  Involvement of 5-HT1B receptors in collar-induced hypersensitivity to 5-hydroxytryptamine of the rabbit carotid artery.

Authors:  I S Geerts; K E Matthys; A G Herman; H Bult
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Collar-induced elevation of mRNA and functional activity of 5-HT(1B) receptor in the rabbit carotid artery.

Authors:  I S Geerts; G R De Meyer; H Bult
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients.

Authors:  N P Chau; I Pithois-Merli; J Levenson; A C Simon
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.

Authors:  D J Stott; A R Saniabadi; J Hosie; G D Lowe; S G Ball
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Vasoconstrictor and vasodilator responses to tryptamine of rat-isolated perfused mesentery: comparison with tyramine and β-phenylethylamine.

Authors:  M A Anwar; W R Ford; K J Broadley; A A Herbert
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Ritanserin blocks CaV1.2 channels in rat artery smooth muscles: electrophysiological, functional, and computational studies.

Authors:  Fabio Fusi; Alfonso Trezza; Giampietro Sgaragli; Ottavia Spiga; Simona Saponara; Sergio Bova
Journal:  Acta Pharmacol Sin       Date:  2020-03-04       Impact factor: 6.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.